AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
OncoSil Medical Limited (ASX: OSL) operates in medical devices and is seeking to advance radiation for cancer patients. OncoSilâ¢, a targeted radioactive isotope, is a lead product of the company thatâs implanted straight into the patientâs pancreatic tumours via endoscopic ultrasound.
British Standards Institute, Clinical Oversight Committee reviewing the OncoSil⢠CE Mark file has recently advised the company that it has determined not to give the related approval at this time due to the demonstration of insufficient clinical benefit.
The cash and cash equivalents and financial assets balance of the company stood at $13.0 million as on 31 December 2018, and the group has also received R&D tax incentive refund of $4.3 million during the half year period.
On the price-performance front, the stock of OncoSil Medical Limited was trading at $0.054 (at market close on 29 March 2019) with a market capitalisation of ~$25.23 million. The stock has generated a negative YTD return of 77.14%. Its 52-week high price stands at $0.255 and 52-week low price of $0.021 with an average trading volume of 1,894,897.
Telix Pharmaceuticals Limited (ASX: TLX) has its operations in the health care sector. The company is engaged in the commercialising and development of products related to Molecularly Targeted Radiation for the treatment of cancer and has commercial partnerships with leading healthcare companies globally.
The company has an institutional shareholder base, which includes companies like Fidelity, Acorn Capital, UV Cap. In November 2017, it raised capital of $50 million through Initial Public offering on ASX. The company started early revenue generation from the prostate cancer imaging product.
On the price-performance front, the stock of Telix Pharmaceuticals Limited was trading at $0.840 (at market close on 29 March 2019) with a market capitalisation of $185.61 million. The YTD return for the stock stood at 30.77%. The 52-week high price of the stock stood at $1.030, and the 52-week low price stood at $0.540, with an average trading volume of 115,233.
Kazia Therapeutics Limited (ASX: KZA) has great potential in its pipeline. It aims to realise value for the shareholders and has a team with the experience and expertise to deliver benefit to patients. It is a biotechnology company with a focus on oncology, developing innovative anti-cancer drugs. The company is headquartered in Sydney, Australia.
The company recently entered into an arrangement to sell the remainder of its holding in the ordinary shares of Noxopharm Limited via a single block trade. The company expects to receive ~$2.1 million from the divestment. The proceeds of the transaction will be used for the R&D programs of the company. However, Kazia retains 3 million unlisted options in Noxopharm, with an exercise price of $0.80.
The company reported a cash balance of $5.4 million at 31 December 2018, versus $6.0 million at 30 June 2018. The liquid assets of the company stood at $11.1 million, down from $12.5 million at 30 June 2018, with the reduction largely attributable to the decline in value of the equity holding in Noxopharm Limited.
On the price-performance front, the stock of Kazia Therapeutics Limited was trading at $0.460 (at market close on 29 March 2019) with a market capitalisation of $27.35 million. The stock has generated a YTD return of 29.41%. Its 52-week high price stands at $0.785 and 52-week low price of $0.330 with an average trading volume of 32,263.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
